
    
      To compare survival rates (median and 1-year), and toxicity of two treatment regimens in
      patients with locally advanced incurable NSCLC (study A), to compare survival rates (median
      and 1-year) of two treatment regimens in patients with locally advanced and metastatic NSCLC
      (study B)

      To compare HRQoL and cost effectiveness of two treatment regimens in patients with locally
      advanced incurable NSCLC (study A), and in patients with locally advanced and metastatic
      NSCLC (study B) and to evaluate the effect of HRQoL assessment on QoL dimensions
    
  